WhiteLab raises $26M for AI-designed genomic medicines

WhiteLab Genomics raised $26 million in Series B financing to build AI-designed bio-assets for the next generation of genomic medicines. The company says the round will fund in vivo validation and commercial expansion, building on preclinical delivery work rather than proving a therapy in patients. Teams evaluating AI drug-discovery platforms should read this as a financing and validation milestone, much as Isomorphic Labs’ $2.1 billion raise underscored the capital behind computational drug design.